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   In this month’s WestJEM, Henderson and colleagues report 
on a preliminary study of the genetics of asthma therapy1. 
It seems like a simple enough piece, short, to the point, 
preliminary, not earth-shattering, and yet it points to a brave 
new world, an emerging area of medicine that holds great 
promise. This is about targeting therapy, really targeting 
therapy, dropping the number needed to treat (NNT) as low as 
possible, and dreaming of a number close to one.
   Today in medicine we accept that we must treat many 
patients	with	therapies	to	benefit	just	a	few.	We	accept	that	
of the many treated, many will have side effects and gain 
no	benefit.	We	even	accept	that	some	therapies	will	kill	
patients almost as often as it cures them2. We accept that with 
thrombolytic therapy for myocardial infarction we need to 
treat	between	40	to	100	souls	to	benefit	one	person.	In	patients	
with hypertension we may need to treat hundreds of patients 
for many years before we prevent one death. We accept it, but 
we do not like it.
   In Henderson et al’s paper, the target disease is asthma, the 
treatment is albuterol and the question is, “Can we determine 
with genetic testing which patients are likely to respond and 
which are not?” The study suggests that some patients are 
less or more likely to respond to albuterol and this can be 
predicted	by	their	specific	genetic	profile.	It	could	be	argued,	
and indeed should, that the differences found in the study are 
of	questionable	clinical	significance.	Does	a	difference	of	19%	
in FEV1 really matter? This was not the point of the study, but 
it will be an important question as these studies become more 
prevalent.	Does	knowing	this	patient’s	genetic	profile	really	
change my management or similarly should it change my 
management?  
   It is no secret to the practicing clinician that some patients 
respond very well to a variety of therapies while others appear 
to	gain	no	benefit.	In	asthma	we	have	all	seen	the	patient	
given multiple albuterol treatments to no avail. At the same 
time the patient about to have a respiratory arrest is given 
just a few treatments and responds remarkably well. There is 
clearly a variety of factors that predict response to therapy: the 
patient’s age, sex, race, prior therapies, smoking history, etc. 
At least part of what we are doing by collecting such data as 
sex	and	race	is	genetic	profiling.	We	are	searching	for	those	
patients with the right receptors to our therapy by using the 
blunt instrument of historical and epidemiologic data. Genetic 
testing promises to focus this effort.
   While this area is still in its infancy (the human genome 
project was completed just four years ago), some remarkable 
data	has	been	collected.	In	one	study	of	heart	failure,	a	specific	
genotype was associated with dramatic improvements in LV 
function when these patients were treated with beta-blockers, 
while others gained relatively little effect3. 
   In the end this is all about NNT. Clinicians are crying out for 
new information that can allow them to target therapies to the 
specific	groups	likely	to	gain	the	most	benefit.	We	long	for	the	
Holy Grail, the number needed to treat of one.  
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